Form 4: Recursion Pharmaceuticals CEO Exercises Stock Options and Acquires Shares
SEC Form 4
Christopher Gibson, CEO of Recursion Pharmaceuticals, exercised stock options to acquire 5,000 shares of Class A Common Stock at $2.48 per share on August 29, 2024.
Summary
- On August 29, 2024, Christopher Gibson, the CEO of Recursion Pharmaceuticals, exercised stock options to acquire 5,000 shares of Class A Common Stock at a price of $2.48 per share.
- Following this transaction, Gibson directly owns 757,656 shares of Class A Common Stock.
- Gibson also indirectly owns shares through LAHWRAN-3 LLC (6,176,700 Class A Common Stock), LAHWRAN-4 LLC (388,000 Class A Common Stock), and the Gibson Family Trust (67,875 Class A Common Stock).
- He also holds options to purchase additional shares of Class A Common Stock at various exercise prices and vesting schedules.
Sentiment
Score: 5
Explanation: Neutral. This is a standard SEC filing related to stock option exercises. It doesn't inherently indicate positive or negative sentiment, but rather reflects a transaction that occurred.
Positives
- The CEO's decision to exercise stock options and increase his stake in the company could be interpreted as a positive signal about his confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency of insider transactions. This filing indicates the CEO's recent transaction in the company's stock.
Stakeholder Impact
- The CEO's stock transactions may influence investor sentiment and potentially impact the company's stock price.
Key Dates
| Date | Description |
|---|---|
| 08/29/2024 | Date of transaction: CEO exercised stock options to acquire shares. |
| 12/30/2030 | Expiration date of one of the stock option grants. |
| 02/01/2033 | Expiration date of one of the stock option grants. |
| 02/04/2032 | Expiration date of one of the stock option grants. |
| 02/04/2022 | Start date of one of the stock option grants. |
| 02/09/2034 | Expiration date of one of the stock option grants. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.